Estrogens, Episodic Memory, and Alzheimer's Disease: A Critical Update

 

 Buy Article Permissions and Reprints

ABSTRACT

Estrogen-containing hormone therapy initiated during late postmenopause does not improve episodic memory (an important early symptom of Alzheimer's disease), and it increases dementia risk. Cognitive consequences of exogenous estrogen exposures during midlife are less certain. Observational evidence implies that use of hormone therapy at a younger age close to the time of menopause may reduce risk of Alzheimer's disease later in life. However, there are concerns that observational findings may be systematically biased. Partial insight on this critical issue may be gleaned from results of ongoing clinical trials involving midlife postmenopausal women (Early versus Late Intervention Trial with Estrogen; Kronos Early Estrogen Prevention Study). The effects of exogenous midlife estrogen exposures and Alzheimer risk can also be approached through better animal models, through carefully designed cohort studies, and through use of surrogate outcomes in randomized controlled trials in midlife women. Selective estrogen receptor modulators have the potential to affect cognitive outcomes and also merit additional study.

REFERENCES

• 1 Judd H L, Fournet N. Changes of ovarian hormonal function with aging.  Exp Gerontol. 1994;  29 285-298
  CrossrefPubMedGoogle Scholar
• 2 Guthrie J R, Dennerstein L, Taffe J R, Lehert P, Burger H G. The menopausal transition: a 9-year prospective population-based study. The Melbourne Women's Midlife Health Project.  Climacteric. 2004;  7 375-389
  CrossrefPubMedGoogle Scholar
• 3 Davison S, Bell R, Donath S, Montalto J, Davis S R. Androgen levels in adult females: changes with age, menopause and oophorectomy.  J Clin Endocrinol Metab. 2005;  90 3847-3853
  CrossrefPubMedGoogle Scholar
• 4 Shaywitz S E, Shaywitz B A, Pugh K R et al.. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks.  JAMA. 1999;  281 1197-1202
  CrossrefPubMedGoogle Scholar
• 5 Launer L J, Andersen K, Dewey M E et al.. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses.  Neurology. 1999;  52 78-84
  PubMedGoogle Scholar
• 6 Kukull W A, Higdon R, Bowen J D et al.. Dementia and Alzheimer disease incidence: a prospective cohort study.  Arch Neurol. 2002;  59 1737-1746
  CrossrefPubMedGoogle Scholar
• 7 Gao S, Hendrie H C, Hall K S, Hui S. The relationships between age, sex, and incidence of dementia and Alzheimer disease: a meta-analysis.  Arch Gen Psychiatry. 1998;  55 809-815
  CrossrefPubMedGoogle Scholar
• 8 Schneider J A, Arvanitakis Z, Bang W, Bennett D A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons.  Neurology. 2007;  69 2197-2204
  CrossrefPubMedGoogle Scholar
• 9 Petersen R C, Smith G E, Waring S C, Ivnik R J, Tangalos E G, Kokmen E. Mild cognitive impairment: clinical characterization and outcome.  Arch Neurol. 1999;  56 303-308
  CrossrefPubMedGoogle Scholar
• 10 Woolley C S, McEwen B S. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat.  J Comp Neurol. 1993;  336 293-306
  CrossrefPubMedGoogle Scholar
• 11 Foy M R, Henderson V W, Berger T W, Thompson R F. Estrogen and neural plasticity.  Curr Dir Psychol Sci. 2000;  9 148-152
  CrossrefPubMedGoogle Scholar
• 12 Tanapat P, Hastings N B, Reeves A J, Gould E. Estrogen stimulates a transient increase in the number of new neurons in the dentate gyrus of the adult female rat.  J Neurosci. 1999;  19 5792-5801
  PubMedGoogle Scholar
• 13 Goodman Y, Bruce A J, Cheng B, Mattson M P. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons.  J Neurochem. 1996;  66 1836-1844
  PubMedGoogle Scholar
• 14 Petanceska S S, Nagy G, Frail D, Gandy S. Ovariectomy and 17β-estradiol modulate the levels of Alzheimer's amyloid β peptides in brain.  Neurology. 2000;  54 2212-2217
  PubMedGoogle Scholar
• 15 Shughrue P J, Scrimo P J, Merchenthaler I. Evidence for the colocalization of estrogen receptor-beta mRNA and estrogen receptor-alpha immunoreactivity in neurons of the rat forebrain.  Endocrinology. 1998;  139 5267-5270
  CrossrefPubMedGoogle Scholar
• 16 Luine V. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats.  Exp Neurol. 1985;  89 484-490
  CrossrefPubMedGoogle Scholar
• 17 Kimura D, Hampson E. Cognitive pattern in men and women is influenced by fluctuations in sex hormones.  Curr Dir Psychol Sci. 1994;  3 57-61
  CrossrefPubMedGoogle Scholar
• 18 Phillips S M, Sherwin B B. Effects of estrogen on memory function in surgically menopausal women.  Psychoneuroendocrinology. 1992;  17 485-495
  CrossrefPubMedGoogle Scholar
• 19 Sherwin B B, Tulandi T. “Add-back” estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri.  J Clin Endocrinol Metab. 1996;  81 2545-2549
  CrossrefPubMedGoogle Scholar
• 20 Xu J, Bartoces M, Neale A V, Dailey R K, Northrup J, Schwartz K L. Natural history of menopause symptoms in primary care patients: a MetroNet study.  J Am Board Fam Pract. 2005;  18 374-382
  CrossrefPubMedGoogle Scholar
• 21 Henderson V W, Dudley E C, Guthrie J R, Burger H G, Dennerstein L. Estrogen exposures and memory at midlife: a population-based study of women.  Neurology. 2003;  60 1369-1371
  PubMedGoogle Scholar
• 22 Herlitz A, Thilers P, Habib R. Endogenous estrogen is not associated with cognitive performance before, during, or after menopause.  Menopause. 2007;  14 425-431
  CrossrefPubMedGoogle Scholar
• 23 Kok H S, Kuh D, Cooper R et al.. Cognitive function across the life course and the menopausal transition in a British birth cohort.  Menopause. 2006;  13 19-27
  CrossrefPubMedGoogle Scholar
• 24 Fuh J-L, Wang S-J, Lee S-J, Lu S-R, Juang K-D. A longitudinal study of cognition change during early menopausal transition in a rural community.  Maturitas. 2006;  53 447-453
  CrossrefPubMedGoogle Scholar
• 25 Luetters C, Huang M H, Seeman T et al.. Menopause transition stage and endogenous estradiol and follicle-stimulating hormone levels are not related to cognitive performance: cross-sectional results from the study of women's health across the nation (SWAN).  J Womens Health. 2007;  16 331-344
  CrossrefPubMedGoogle Scholar
• 26 Neugarten B L, Kraines R J. “Menopausal symptoms” in women of various ages.  Psychosom Med. 1965;  27 266-273
  PubMedGoogle Scholar
• 27 Henderson V W, Sherwin B B. Surgical versus natural menopause: cognitive issues.  Menopause. 2007;  14 572-579
  CrossrefPubMedGoogle Scholar
• 28 Maki P M, Gast M J, Vieweg A, Burriss S W, Yaffe K. Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial.  Neurology. 2007;  69 1322-1330
  CrossrefPubMedGoogle Scholar
• 29 Sherwin B B. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women.  Psychoneuroendocrinology. 1988;  13 345-357
  CrossrefPubMedGoogle Scholar
• 30 Espeland M A, Rapp S R, Shumaker S A et al.. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.  JAMA. 2004;  291 2959-2968
  CrossrefPubMedGoogle Scholar
• 31 Resnick S M, Maki P M, Rapp S R et al.. Effects of combination estrogen plus progestin hormone treatment on cognition and affect.  J Clin Endocrinol Metab. 2006;  91 1802-1810
  CrossrefPubMedGoogle Scholar
• 32 Almeida O P, Lautenschlager N T, Vasikaran S, Leedman P, Gelavis A, Flicker L. 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life.  Neurobiol Aging. 2006;  27 141-149
  CrossrefPubMedGoogle Scholar
• 33 Yaffe K, Vittinghoff E, Ensrud K E et al.. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life.  Arch Neurol. 2006;  63 945-950
  CrossrefPubMedGoogle Scholar
• 34 Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study.  Am J Med. 2002;  113 543-548
  CrossrefPubMedGoogle Scholar
• 35 Viscoli C M, Brass L M, Kernan W N, Sarrel P M, Suissa S, Horwitz R I. Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST).  Am J Obstet Gynecol. 2005;  192 387-393
  CrossrefPubMedGoogle Scholar
• 36 Asthana S, Baker L D, Craft S et al.. High-dose estradiol improves cognition for women with AD: results of a randomized study.  Neurology. 2001;  57 605-612
  PubMedGoogle Scholar
• 37 Henderson V W, Paganini-Hill A, Miller B L et al.. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial.  Neurology. 2000;  54 295-301
  PubMedGoogle Scholar
• 38 Wang P N, Liao S Q, Liu R S et al.. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study.  Neurology. 2000;  54 2061-2066
  PubMedGoogle Scholar
• 39 Mulnard R A, Cotman C W, Kawas C et al.. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial.  JAMA. 2000;  283 1007-1015
  CrossrefPubMedGoogle Scholar
• 40 Rigaud A S, Andre G, Vellas B, Touchon J, Pere J J. No additional benefit of HRT on response to rivastigmine in menopausal women with AD.  Neurology. 2003;  60 148-149
  CrossrefPubMedGoogle Scholar
• 41 Henderson V W, Paganini-Hill A, Emanuel C K, Dunn M E, Buckwalter J G. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects.  Arch Neurol. 1994;  51 896-900
  PubMedGoogle Scholar
• 42 Schneider L S, Farlow M R, Henderson V W, Pogoda J M. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.  Neurology. 1996;  46 1580-1584
  PubMedGoogle Scholar
• 43 Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women.  JAMA. 1998;  279 688-695
  CrossrefPubMedGoogle Scholar
• 44 Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis.  Neuroscience. 2000;  101 485-512
  CrossrefPubMedGoogle Scholar
• 45 Petitti D B, Buckwalter J G, Crooks V C, Chiu V. Prevalence of dementia in users of hormone replacement therapy as defined by prescription data.  J Gerontol A Biol Sci Med Sci. 2002;  57 M532-M538
  PubMedGoogle Scholar
• 46 Brenner D E, Kukull W A, Stergachis A et al.. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study.  Am J Epidemiol. 1994;  140 262-267
  PubMedGoogle Scholar
• 47 Seshadri S, Zomberg G L, Derby L E, Myers M W, Jick H, Drachman D A. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease.  Arch Neurol. 2001;  58 435-440
  CrossrefPubMedGoogle Scholar
• 48 Waring S C, Rocca W A, Petersen R C, O'Brien P C, Tangalos E G, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study.  Neurology. 1999;  52 965-970
  PubMedGoogle Scholar
• 49 Roberts R O, Cha R H, Knopman D S, Petersen R C, Rocca W A. Postmenopausal estrogen therapy and Alzheimer disease: overall negative findings.  Alzheimer Dis Assoc Disord. 2006;  20 141-146
  CrossrefPubMedGoogle Scholar
• 50 Paganini-Hill A, Henderson V W. Estrogen replacement therapy and risk of Alzheimer's disease.  Arch Intern Med. 1996;  156 2213-2217
  CrossrefPubMedGoogle Scholar
• 51 Tang M-X, Jacobs D, Stern Y et al.. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.  Lancet. 1996;  348 429-432
  CrossrefPubMedGoogle Scholar
• 52 Kawas C, Resnick S, Morrison A et al.. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging.  Neurology. 1997;  48 1517-1521
  PubMedGoogle Scholar
• 53 Zandi P P, Carlson M C, Plassman B L et al.. Hormone replacement therapy and incidence of Alzheimer's disease on older women: the Cache County study.  JAMA. 2002;  288 2123-2129
  CrossrefPubMedGoogle Scholar
• 54 Shumaker S A, Legault C, Rapp S R et al.. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study (WHIMS).  JAMA. 2003;  289 2651-2662
  CrossrefPubMedGoogle Scholar
• 55 Shumaker S A, Legault C, Kuller L et al.. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.  JAMA. 2004;  291 2947-2958
  CrossrefPubMedGoogle Scholar
• 56 Henderson V W, Espeland M A, Hogan P E et al.. Prior use of hormone therapy and incident Alzheimer's disease in the Women's Health Initiative Memory Study [abstract].  Neurology. 2007;  68(Suppl 1) A205
  PubMedGoogle Scholar
• 57 Henderson V W. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research.  Neuroscience. 2006;  138 1031-1039
  CrossrefPubMedGoogle Scholar
• 58 Brett K M, Chong Y. Hormone Replacement Therapy: Knowledge and Use in the United States. Hyattsville, MD; National Center for Health Statistics 2001
  Google Scholar
• 59 Resnick S M, Henderson V W. Hormone therapy and risk of Alzheimer disease: a critical time.  JAMA. 2002;  288 2170-2172
  CrossrefPubMedGoogle Scholar
• 60 Henderson V W, Benke K S, Green R C, Cupples L A, Farrer L A. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age.  J Neurol Neurosurg Psychiatry. 2005;  76 103-105
  CrossrefPubMedGoogle Scholar
• 61 Elias M F, Beiser A, Wolf P A, Au R, White R F, D'Agostino R B. The preclinical phase of Alzheimer's disease: a 22-year prospective study of the Framingham cohort.  Arch Neurol. 2000;  57 808-813
  CrossrefPubMedGoogle Scholar
• 62 Carroll J C, Rosario E R, Chang L et al.. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice.  J Neurosci. 2007;  27 13357-13365
  CrossrefPubMedGoogle Scholar
• 63 Alvarez-De-La-Rosa M, Silva I, Nilsen J et al.. Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease.  Ann N Y Acad Sci. 2005;  1052 210-224
  CrossrefPubMedGoogle Scholar
• 64 Umetani M, Domoto H, Gormley A K et al.. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen.  Nat Med. 2007;  13 1185-1192
  PubMedGoogle Scholar
• 65 Hodis H N, Mack W J, Lobo R A et al.. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 2001;  135 939-953
  CrossrefPubMedGoogle Scholar
• 66 Hodis H N, Mack W J, Azen S P et al.. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women.  N Engl J Med. 2003;  349 535-545
  CrossrefPubMedGoogle Scholar
• 67 Clarkson T B. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression.  Menopause. 2007;  14 373-384
  CrossrefPubMedGoogle Scholar
• 68 Rossouw J E, Prentice R L, Manson J E et al.. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.  JAMA. 2007;  297 1465-1477
  CrossrefPubMedGoogle Scholar
• 69 Coker L H, Hogan P E, Bryan N R et al.. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study.  Neurology. 2009;  72 125-134
  CrossrefPubMedGoogle Scholar
• 70 Landry M, Levesque D, Di Paolo T. Estrogenic properties of raloxifene, but not tamoxifen, on D₂ and D₃ dopamine receptors in the rat forebrain.  Neuroendocrinology. 2002;  76 214-222
  CrossrefPubMedGoogle Scholar
• 71 Zhou W, Koldzic-Zivanovic N, Clarke C H et al.. Selective estrogen receptor modulator effects in the rat brain.  Neuroendocrinology. 2002;  75 24-33
  CrossrefPubMedGoogle Scholar
• 72 Yaffe K, Krueger K, Sarkar S et al.. Cognitive function in postmenopausal women treated with raloxifene.  N Engl J Med. 2001;  344 1207-1213
  CrossrefPubMedGoogle Scholar
• 73 Yaffe K, Krueger K, Cummings S R et al.. Effect of raloxifene on the prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.  Am J Psychiatry. 2005;  162 683-690
  CrossrefPubMedGoogle Scholar
• 74 Paganini-Hill A, Clark L J. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen.  Breast Cancer Res Treat. 2000;  64 165-176
  CrossrefPubMedGoogle Scholar
• 75 Patisaul H B, Dindo M, Whitten P L, Young L J. Soy isoflavone supplements antagonize reproductive behavior and estrogen receptor α- and β-dependent gene expression in the brain.  Endocrinology. 2001;  142 2946-2952
  CrossrefPubMedGoogle Scholar
• 76 Kuiper G G, Lemmen J G, Carlsson B et al.. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.  Endocrinology. 1998;  139 4252-4263
  CrossrefPubMedGoogle Scholar
• 77 White L R, Petrovitch H, Ross G W et al.. Brain aging and midlife tofu consumption.  J Am Coll Nutr. 2000;  19 242-255
  PubMedGoogle Scholar
• 78 North American Menopause Society . Estrogen and progestogen use in postmenopausal women: July 2008 position statement of the North American Menopause Society.  Menopause. 2008;  15 584-602
  CrossrefPubMedGoogle Scholar

Victor W HendersonM.D. 

Stanford University, 259 Campus Drive, HRP Redwood Building

Stanford, CA 94305-5405

Email: vhenderson@stanford.edu